Key result
Hospital Readmissions Reduction Program linked to a minimal ~1% drop in HFrEF and HFpEF readmissions.
Why the study?
Recent Medicare analyses questioned the effectiveness of the Hospital Readmission Reduction Program, and its impact had not been evaluated across heart failure subtypes.
Does the Hospital Readmissions Reduction Program (HRRP) reduce readmissions and inpatient mortality in patients with heart failure subtypes (HFrEF and HFpEF)?
Observational (n=7,274,860)
Yes
Does the Hospital Readmissions Reduction Program (HRRP) reduce readmissions and inpatient mortality in patients with heart failure subtypes (HFrEF and HFpEF)?
Absolute Event Rate: 21.4% vs 22.3%
p-value: p=<0.001
The Hospital Readmissions Reduction Program was associated with only minimal reductions in readmission rates and inpatient mortality across both HFrEF and HFpEF subtypes.
HRRP's minimal readmission reductions in HFrEF and HFpEF warrant policy caution; leaves open whether incentives meaningfully improve HF outcomes.
Background: The Hospital Readmission Reduction Program (HRRP) sought to reduce readmissions by penalising centres with readmissions above the national average, and heart failure (HF) is the leading driver of the readmission penalty. Recent Medicare analyses question the effectiveness of this strategy. This study evaluated the efficacy of HRRP by utilising large national datasets and is the first to analyse based on heart failure subtypes. Methods: Aggregate data was used from the National Inpatient Sample (NIS) to study mortality and the National Readmissions Database (NRD) to study readmissions. Both included all payer-types and were stratified by heart failure subtype and time (pre- and post-HRRP implementation). Results: Patients with HF with preserved ejection fraction (HFpEF) tended to be older females with a higher proportion of comorbidities compared to patients with HF with reduced ejection fraction (HFrEF). In the post-HRRP period, readmission rates decreased for HFrEF (21.4% versus 22.3%, p<0.001) and HFpEF (21.2% versus 22.4%, p<0.001); readmission rates for the two subtypes were not statistically different compared to the other. Post-HRRP, inpatient mortality was consistent for HFrEF (2.8% versus 2.8%, p=0.087), but decreased for HFpEF (2.4% versus 2.5%, p=0.029). There were no significant differences noted in average length of stay. Patients with HFrEF were more frequently discharged to short-term hospitals or home with home healthcare, and patients with HFpEF were discharged to skilled nursing facilities more often. Estimated inpatient costs decreased in both subtypes post-HRRP, but readmission costs were higher for HFrEF. Conclusions: This study suggests that HRRP was associated with minimal change in readmission and inpatient mortality.
No takes yet. Share an insight, caveat, or question.
Sheikh et al. (2021) conducted an observational in Heart failure (HFrEF and HFpEF) (n=7,274,860). Hospital Readmissions Reduction Program (HRRP) vs. Pre-HRRP period was evaluated on Readmission rate for HFrEF (p=<0.001). The Hospital Readmissions Reduction Program was associated with minimal decreases in readmission rates for both HFrEF (from 22.3% to 21.4%) and HFpEF (from 22.4% to 21.2%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: